wsbdaily | Tue, 20 Dec 2022 03:11:28 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
TRACON Pharmaceuticals, Inc.(TCON)
TRACON Pharmaceuticals, Inc.
4350 La Jolla Village Drive
Suite 800
San Diego, CA 92122
United States
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase... Read More
Summary & Charts
| Price | $ 1.29 | +0.07 (+5.73%) |
| Day's Range | $ 1.19 - 1.36 | |
| Previous Close | $ 1.22 | |
| Market Cap | $ 28.43M USD | |
| Short Interest % | 0.73 % | As of Fri, 14 Jan 2022 |
| Float | 19.88M | |
| Outstanding | 22.21M |
| Exchange | NasdaqCM | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 274.53K | |
| Avg. Volume (20 day) | 266.77K | |
| Rel. Volume (20 day) | 1.03 | |
| Rel. Volume (3 month) | 1.92 | |
| Rating | B- | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | -846.34 % | Strong Sell |
| ROE | -828.53 % | Strong Buy |
| ROA | -151.78 % | Strong Sell |
| P/E | -0.71 % | Sell |
| P/B | -10.51 % | Strong Sell |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Dec 19, 2022 | $ 1.20 | $ 1.36 | $ 1.19 | $ 1.29 | +0.07 | 274,529 | 1.03 | 1.92 | 1 |
| Dec 16, 2022 | $ 1.26 | $ 1.30 | $ 1.15 | $ 1.22 | -0.06 | 184,965 | 0.72 | 1.34 | |
| Dec 15, 2022 | $ 1.33 | $ 1.36 | $ 1.23 | $ 1.28 | -0.01 | 460,690 | 1.82 | 3.41 | 1 |
| Dec 14, 2022 | $ 1.50 | $ 1.61 | $ 1.10 | $ 1.29 | -0.02 | 3,616,389 | 15.54 | 28.28 | |
| Dec 13, 2022 | $ 1.40 | $ 1.40 | $ 1.28 | $ 1.31 | +0.02 | 158,332 | 2.75 | 2.14 | |
| Dec 12, 2022 | $ 1.32 | $ 1.32 | $ 1.27 | $ 1.29 | -0.03 | 70,076 | 1.11 | 0.97 | |
| Dec 09, 2022 | $ 1.31 | $ 1.35 | $ 1.31 | $ 1.32 | -0.03 | 85,925 | 1.33 | 1.21 | |
| Dec 08, 2022 | $ 1.41 | $ 1.42 | $ 1.31 | $ 1.35 | -0.06 | 88,870 | 1.42 | 1.28 | |
| Dec 07, 2022 | $ 1.45 | $ 1.45 | $ 1.41 | $ 1.41 | -0.04 | 28,071 | 0.43 | 0.41 | |
| Dec 06, 2022 | $ 1.44 | $ 1.48 | $ 1.43 | $ 1.45 | +0.01 | 41,602 | 0.62 | 0.61 | |
| Dec 05, 2022 | $ 1.50 | $ 1.50 | $ 1.44 | $ 1.44 | -0.06 | 69,536 | 1.00 | 1.04 | |
| Dec 02, 2022 | $ 1.47 | $ 1.50 | $ 1.44 | $ 1.50 | +0.00 | 22,287 | 0.32 | 0.33 | |
| Dec 01, 2022 | $ 1.50 | $ 1.52 | $ 1.48 | $ 1.50 | -0.01 | 25,514 | 0.34 | 0.38 | |
| Nov 30, 2022 | $ 1.50 | $ 1.51 | $ 1.48 | $ 1.50 | +0.00 | 22,772 | 0.30 | 0.33 | |
| Nov 29, 2022 | $ 1.51 | $ 1.52 | $ 1.49 | $ 1.50 | 26,270 | 0.35 | 0.38 | ||
| Nov 28, 2022 | $ 1.48 | $ 1.53 | $ 1.47 | $ 1.50 | +0.01 | 32,899 | 0.41 | 0.47 | |
| Nov 25, 2022 | $ 1.50 | $ 1.51 | $ 1.49 | $ 1.49 | -0.02 | 2,399 | 0.03 | 0.03 | |
| Nov 23, 2022 | $ 1.50 | $ 1.52 | $ 1.48 | $ 1.51 | +0.02 | 18,789 | 0.23 | 0.26 | |
| Nov 22, 2022 | $ 1.47 | $ 1.51 | $ 1.43 | $ 1.49 | +0.05 | 34,520 | 0.40 | 0.48 | |
| Nov 21, 2022 | $ 1.44 | $ 1.48 | $ 1.43 | $ 1.44 | +0.04 | 70,956 | 0.82 | 0.98 |
News
The latest news about TRACON Pharmaceuticals, Inc. (TCON).
Seeking Alpha | 2022-11-30 01:43:07
Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors.
Proactive Investors | 2022-11-21 08:41:06
TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin, in front line therapy of patients with malignant tumours. The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma sub-types of leiomyosarcoma and dedifferentiated liposarcoma, according to TRACON.
Seeking Alpha | 2022-11-14 22:43:02
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Joel Beatty - Robert W. Baird & Co. Edward White - H.C.
Proactive Investors | 2022-11-14 16:45:02
TRACON Pharmaceuticals Inc announced that it has ended its third-quarter 2022 with cash and equivalents of $17.0 million as of September 30, 2022, which the company says is expected to fund its operations into mid-2023. The clinical stage biopharmaceutical company also noted that its net loss for the quarter narrowed to $6.4 million from $7.0 million a year earlier, as it reduced its general and administrative expenses for the period to $2.3 million, compared to $4.2 million in 3Q 2021.
Proactive Investors | 2022-10-06 10:07:38
TRACON Pharmaceuticals Inc has received a recommendation from the Independent Data Monitoring Committee that its ENVASARC Phase 2 pivotal trial can proceed as planned, the company announced. The committee made its recommendation following a review of 12-week safety data from patients enrolled in the trial as of June 30.
InvestorPlace | 2022-10-05 11:00:26
In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-14 | AMC | -0.28 | -0.30 | 7.14% | -- | -- | -- |
| 2022-08-10 | AMC | -0.37 | -0.31 | 16.22% | -- | -- | -- |
| 2022-05-11 | AMC | -0.42 | -0.48 | 14.28% | -- | -- | -- |
| 2022-03-15 | AMC | -0.35 | -0.40 | 14.28% | 80K | -- | -- |
| 2021-11-03 | AMC | -0.32 | -0.38 | 18.75% | -- | -- | -- |
| 2021-08-11 | AMC | -0.34 | -0.58 | 70.58% | 252K | 346K | 37.37% |
| 2021-05-05 | AMC | -0.3 | -0.33 | 10% | -- | -- | -- |
| 2021-02-25 | AMC | -0.41 | -0.31 | 24.4% | -- | -- | -- |
Top Discussions
These are the top discussions over the last 24-hours that mention the TCON stock ticker symbol.
Daily Plays December 19, 2022
Talk about your plays today or things you are on the lookout for. This is where you belong if your comment includes a $Ticker in that format. ​ *keep it civil please*...
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Mon, 13 Dec 2021 12:00 EST
@wsbdaily
wsbdaily